Trial Profile
A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Grass SPIRE (Primary)
- Indications Allergic rhinitis; Conjunctivitis; Grass pollen hypersensitivity
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Niox
- 21 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 16 Jun 2016 New trial record